Welcome to our dedicated page for Immatics N.V. Ordinary Shares news (Ticker: IMTX), a resource for investors and traders seeking the latest updates and insights on Immatics N.V. Ordinary Shares stock.
Immatics N.V. (NASDAQ: IMTX) is a pioneering clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative T-cell redirecting immunotherapies for cancer treatment. Headquartered in both Germany and Switzerland, Immatics harnesses cutting-edge biotechnology to create transformative therapies aimed at combating various forms of cancer.
The company's core product candidates include adoptive cell therapies and bispecific TCR molecules. These therapies are designed to target tumor-specific antigens identified through Immatics' proprietary and world-leading XPRESIDENT® technology platform. This platform enables the precise identification and validation of tumor targets, ensuring the development of highly specific and effective cancer treatments.
Immatics is structured around two proprietary technology platforms and actively manages eight proprietary development programs, with two programs already in clinical trials as of 2017. The company's robust research pipeline covers more than 100 targets across 20 major solid and liquid tumors, with approximately 80% of these targets being novel discoveries.
Recent financial successes underscore Immatics' growth and potential; the company has raised over $230 million in cash through five financing rounds. This substantial funding supports their mission to advance T-cell redirecting immunotherapies and bring new hope to cancer patients worldwide.
Immatics collaborates with numerous third-party pharmaceutical and biotechnology companies, forming strategic partnerships to further enhance the development and commercialization of their innovative therapies. The company's commitment to innovation and collaboration positions it as a leader in the biopharmaceutical industry.
For more detailed information, including the latest updates and financial results, visit the Immatics website or follow them on Twitter and Xing.
Immatics N.V. (NASDAQ: IMTX) reported significant advancements in its ACTengine® IMA203 TCR-T immunotherapy, showing a 50% confirmed objective response rate (cORR) across various solid tumors in an interim update. The company plans to prioritize 1st and 2nd-generation monotherapy treatments in pivotal trials by 2H 2023. Progress includes the establishment of an in-house GMP manufacturing facility scheduled for 2024, enhancing production capacity. Financially, total revenue surged to €172.8 million in 2022, marking a substantial increase from €34.8 million in 2021, with a net profit of €37.5 million.
Seamless Therapeutics has secured
Immatics N.V. (NASDAQ: IMTX) reported an interim clinical update on ACTengine® IMA203, noting a confirmed objective response rate (cORR) of 50% from Phase 1 trials. The initial results indicate promising efficacy across various solid tumors, including melanoma and ovarian cancer. The company also announced the ongoing treatment of patients with its 2nd generation TCR-T candidate, IMA203CD8, and plans to start a Phase 1/2 trial for TCER® IMA402 in 2023. Financially, Immatics has €309.3 million in cash, projected to fund operations into 2025, and reported a revenue increase to €15.1 million for Q3 2022.
FAQ
What is the current stock price of Immatics N.V. Ordinary Shares (IMTX)?
What is the market cap of Immatics N.V. Ordinary Shares (IMTX)?
What does Immatics N.V. do?
What are Immatics' core product candidates?
What is XPRESIDENT® technology?
How many targets does Immatics' research cover?
What is the company's financial status?
Are Immatics' therapies in clinical trials?
Who are Immatics' partners?
Where is Immatics headquartered?
What is the company's mission?
How can I learn more about Immatics?
